Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Inhalt archiviert am 2024-06-18

Bottom-up reconstitution of a biomimetic bioartificial liver

Ziel

The liver, by way of its central role in both endogenous and exogenous metabolism, is one of the most well-studied organs in the human body.
Hepatic tissue and its derivatives have a wide range of in-vivo and in-vitro applications from whole organ or partial lobe transplant, bioartificial ex-vivo devices, treatment of metabolic disorders to toxicology, drug metabolism and tissue regeneration. On the one hand, suitable donor livers for solid organ transplant are in short supply, while chronic liver diseases are on the increase both in Europe and world-wide. On the other hand, in-vitro and ex-vivo technologies for recapitulating liver function still fall short of reliability, consistency and predictivity, precluding many commercial applications. There is a dire need for innovative and reproducible methods for developing functional bioartificial livers or portions of liver which can be easily transplanted or reliably integrated into extracorporeal devices, essential for treating acute liver failure and other metabolic liver disorders. To avoid the risks and complications associated with animal/human matrices, yet furnish a reliable and reproducible 3D microarchitecture capable of maintaining the detoxification and metabolic functions of healthy human liver, our aim is to fabricate a novel hepatic lobuli ECM replica seeded with stable human hepatocytes and endothelial cells using the human liver as a design template through a bottom up approach. These cell-containing bioartificial constructs will be developed and characterized in vitro to assess metabolic function, protein production and angiogenic potential. They will then be implanted in animal models through minimally invasive techniques as a solid organ transplant alternative to recombinant Factor VIII-based therapy for patients with haemophilia A.

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2012-INNOVATION-2
Andere Projekte für diesen Aufruf anzeigen

Koordinator

UNIVERSITA DI PISA
EU-Beitrag
€ 824 999,00
Adresse
LUNGARNO PACINOTTI 43/44
56126 Pisa
Italien

Auf der Karte ansehen

Region
Centro (IT) Toscana Pisa
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Immacolata Viva (Dr.)
Links
Gesamtkosten
Keine Daten

Beteiligte (4)